Pregnant woman with Eisenmenger’s syndrome (RCD code: VII-II-1A.4d)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2013, Vol 1, Issue 3
Abstract
Pregnancy in women with pulmonary arterial hypertension due to congenital heart disease is associated with significant morbidity and mortality both in the mother and fetus. We report a case of a 25-year-old woman with Eisenmenger’s syndrome who got pregnant when treated with bosentan. Bosentan was changed to sildenafil. During the course of pregnancy she developed ischemic stroke. She delivered in the 33 week of gestation. We present our treatment approach and review the current literature on pregnany in pulmonary arterial hypertension. JRCD 2013; 1 (3): 27–31
Authors and Affiliations
Grzegorz Kopeć, Agata Leśniak-Sobelga, Magdalena Kaźnica-Waitr, Anna Tyrka, Marcin Waligóra, Krzysztof Rytlewski, Piotr Podolec
Keywords
Related Articles
- EP ID EP245389
- DOI 10.20418/jrcd.vol1no3.74
- Views 110
- Downloads 0
Cardiac Tumours and Malignancy Diseases
n/a
Superior vena cava syndrome associated with implantable cardiac devices procedures
INTRODUCTION: Superior vena cava (SVC) syndrome is a rare clinical disorder associated with obstructing venous outflow through the SVC. Although the most common cause is mediastinal tumors, the growing number of impla...
Combination therapy in the treatment of pulmonary arterial hypertension - 2015 update.
Pulmonary arterial hypertension (PAH) is a disease with a poor prognosis and high mortality rates therefore in the era of advanced therapies targeting different patophysiological pathways attractive seems the idea of com...
Influence of disease‑related heart pathology on peak oxygen uptake and ventilation/carbon dioxide output ratio in systemic sclerosis and systemic lupus erythematosus patients (RCD code: I-3C)
Background: Exercise capacity is an independent predictor of mortality in the general population. However, available literature has been focused mainly on exercise testing in patients with ischaemic heart failure. Little...
Establishing the optimal dose of nitric oxide in acute vasoreactivity testing in patients with pulmonary hypertension with use of the Bronchial Control Treatment System (RCD code: II)
The key point in the diagnostic algorithm for pulmonary hypertension plays the pulmonary reactivity testing, the agent most frequently used in the test is inhaled nitric oxide (iNO). Various dosages of iNO were used in a...